Overall, EPS has differential activity on breast cancer cells that does not require TLR4, unlike previous studies showing that TLR4 signaling is required on myeloid cells for the anti-inflammatory effect of EPS (39–41). The gene discussed is TLR4; the disease is breast carcinoma.